ASPREE Project News
Update: ASPREE-XT study visits and COVID-19
Important information about ASPREE-XT study visits and COVID-19 The ASPREE-XT study team continues to adapt...
Observational statin study in ASPREE participants
Statins may prevent heart attacks and strokes but may not prolong life free of disability PRESS RELEASE...
Low-dose aspirin and depression
ASPREE-D sub-study finds daily aspirin not protective against late-life depression PRESS RELEASE: 4th June 2020...
Aspirin and cognitive decline
Daily low-dose aspirin does not prevent cognitive decline in healthy older adults PRESS RELEASE: 1st...
ASPREE-XT 2019 in summary
A year of major achievements for long-term aspirin study This year, we welcomed a mid-year announcement that...
ASPREE’s Australian award trifecta
Impact of ASPREE trial on public health recognised We are pleased to share three Australian research...
NIH funds ASPREE-XT (eXTension) study
Landmark study to assess long-term health risks and benefits of prior aspirin use in elderly PRESS RELEASE ...
Researchers from National Cancer Institute (NCI) visit ASPREE
A welcome to Melbourne Australian ASPREE investigators welcomed members from the National Cancer Institute...
US heart specialists pen importance of ASPREE trial to clinicians
The ASPREE Aftermath: A Geriatric Perspective on the Role of Aspirin in Older Adults Thanks to...
ASPREE publishes trial results in New England Journal of Medicine today!
Daily low-dose aspirin doesn't reduce heart-attack risk in healthy people For decades, doctors have been prescribing...